NVCR – novocure limited - ordinary shares (US:NASDAQ)

DELAYED
$ usd
Volume Shares
1 Day Range
Volume Ratio
52 Week High
52 Week Low
VWAP
Today’s Volatility
20 Day Volatility
Open
Prior Close
1D
5D
1M
3M
YTD
1Y
3Y
1 Day NVCR SPY QQQ SPX
Date
Time
Symbol
Company Name
Action
%Chg
5/2/2024
07:00 am
nvcr
novocure limited - ordinary shares
BEAT
9.2%
2/22/2024
07:00 am
nvcr
novocure limited - ordinary shares
BEAT
-3.2%
10/26/2023
07:00 am
nvcr
novocure limited - ordinary shares
BEAT
-9.8%
7/27/2023
07:00 am
nvcr
novocure limited - ordinary shares
MISS
-15.7%
Earnings are essential to understanding the financial health of a company listed on any Stock Exchange. But what are Earnings, how are they calculated, when are they announced, and how are they used to make sound investment decisions?
The answers are right here.
Stock Stats
News Stats
All News
News Wires
Media Monitoring
SEC Edgar Filings
Upgrades
Downgrades
Initiated
Reiterated
Last Earnings
Last Earnings EPS
Next Earnings
Order Stats
Sub-Penny
Odd Lot
Avg. bid-ask spread
Avg. bid / ask size
Shares at ask / bid
Off exchange
Top News Gainers
1/16 Novocure Ltd (NASDAQ: NVCR) was downgraded by analysts at Zacks Investment Research from a "hold" rating to a "sell" rating. 11.0%
7/25 Q2/2019 6/30/2019 EPS -0.010 ZacksConsensus -0.070 ActVsEst 0.060 - Beat 8.6%
3/19 Novocure Announces Optune Lua™ as the Brand Name for the NovoTTF-100L™ System 8.2%
3/4 Novocure Ltd (NASDAQ: NVCR) was downgraded by analysts at BidaskClub from a "hold" rating to a "sell" rating. 7.8%
4/7 Novocure Ltd (NASDAQ: NVCR) is now covered by analysts at Piper Sandler. They set an "overweight" rating and a price target on the stock. 7.7%
5/23 FDA Approves the NovoTTF-100LTM System in Combination with Chemotherapy for the Treatment of Malignant Pleural Mesothelioma 7.3%
6/27 Novocure Ltd (NASDAQ: NVCR) was downgraded by analysts at BidaskClub from a "strong-buy" rating to a "buy" rating. 7.1%
8/14 Form 4 NovoCure Ltd For: Aug 12 Filed by: LEUNG GABRIEL 5.2%
10/31 NovoCure Limited (NVCR) CEO Asaf Danziger on Q3 2019 Results - Earnings Call Transcript [Seeking Alpha] 5.2%
1/7 Novocure Ltd (NASDAQ: NVCR) had its "buy" rating re-affirmed by analysts at Mizuho. They now have a $91.00 price target on the stock. 5.2%
Top News Decliners
4/30 Q1/2020 3/31/2020 EPS 0.040 ZacksConsensus 0.050 ActVsEst (0.010) - Miss -12.1%
3/20 German Federal Joint Committee Updates Medical Care Directive to include Tumor Treating Fields, establishing National Reimbursement for Optune in Germany -10.5%
4/7 Novocure Ltd (NASDAQ: NVCR) had its price target lowered by analysts at Wells Fargo & Co from $90.00 to $82.00. They now have an "overweight" rating on the stock. -9.6%
5/1 Novocure Ltd (NASDAQ: NVCR) had its "hold" rating re-affirmed by analysts at Oppenheimer Holdings Inc.. They now have a $78.00 price target on the stock. -8.4%
9/9 Novocure Announces 27 Presentations at the American Society for Radiation Oncology 2019 Annual Meeting -8.3%
3/10 Form 4 NovoCure Ltd For: Mar 06 Filed by: GROENHUYSEN WILHELMUS CM -8.1%
1/2 Novocure Ltd (NASDAQ: NVCR) was downgraded by analysts at Evercore ISI to an "outperform" rating. -7.9%
3/2 Form 4 NovoCure Ltd For: Feb 27 Filed by: Shah Pritesh -7.4%
10/25 Novocure Ltd (NASDAQ: NVCR) was upgraded by analysts at Zacks Investment Research from a "hold" rating to a "buy" rating. They now have a $79.00 price target on the stock. -6.6%
1/13 Form 8-K NovoCure Ltd For: Jan 10 -5.6%

Don’t Miss Out On The Next BIG Stock Move

Thanks for submitting the form.
NVCR – novocure limited - ordinary shares (US:NASDAQ)
DELAYED
$ usd
1D
5D
1M
3M
YTD
1Y
3Y
Volume Shares
1 Day Range
Volume Ratio
52 Week High
52 Week Low
VWAP
Today’s Volatility
20 Day Volatility
Open
Prior Close
NVCR
SPY
QQQ
SPX
NVCR – novocure limited - ordinary shares (US:NASDAQ)
DELAYED
$ usd
1D
5D
1M
3M
YTD
1Y
3Y
Volume Shares
1 Day Range
Volume Ratio
52 Week High
52 Week Low
VWAP
Today’s Volatility
20 Day Volatility
Open
Prior Close
NVCR SPY QQQ SPX
Stock Stats
All News
News Wires
Media Monitoring
SEC Edgar Filings
Upgrades
Downgrades
Initiated
Reiterated
Last Earnings
Last Earnings EPS
Next Earnings
Sub-Penny
Odd Lot
Avg. bid-ask spread
Avg. bid / ask size
Shares at ask / bid
Off exchange
Stock Stats
Order Stats
Sub-Penny
Odd Lot
Avg. bid-ask spread
Avg. bid / ask size
Shares at ask / bid
Off exchange
News Stats
All News
News Wires
Media Monitoring
SEC Edgar Filings
Upgrades
Downgrades
Initiated
Reiterated
Last Earnings
Last Earnings EPS
Next Earnings
News
5/3
06:20 pm
nvcr
Medium
NovoCure Limited Q1 Earnings: Core Business Accelerating [Seeking Alpha]
5/2
03:21 pm
nvcr
Low
NovoCure Limited (NASDAQ: NVCR) had its "neutral" rating re-affirmed by analysts at Wedbush. They now have a $21.00 price target on the stock.
5/2
01:14 pm
nvcr
High
NovoCure Limited (NASDAQ: NVCR) had its price target lowered by analysts at HC Wainwright from $24.00 to $22.00. They now have a "neutral" rating on the stock.
5/2
07:01 am
nvcr
Medium
Novocure Secures New $400 Million Multi-Tranche Non-Dilutive Debt Financing from Pharmakon
5/2
07:00 am
nvcr
Medium
Novocure Reports First Quarter 2024 Financial Results
4/25
11:44 am
nvcr
Low
NovoCure (NVCR) Expected to Beat Earnings Estimates: Should You Buy? [Yahoo! Finance]
4/24
10:45 am
nvcr
Low
Results of Novocure’s METIS Phase 3 Clinical Trial for Patients with Brain Metastasis from Non-Small Cell Lung Cancer to be Presented as Late-Breaking Abstract at ASCO 2024
4/10
09:08 am
nvcr
Low
NovoCure Limited (NASDAQ: NVCR) had its "overweight" rating re-affirmed by analysts at Piper Sandler. They now have a $28.00 price target on the stock, up previously from $25.00.
4/5
07:00 am
nvcr
Medium
Novocure Announces 20 Presentations On Tumor Treating Fields, Highlighting Preclinical Effects in Pancreatic Cancer and Immune Effects, at American Association for Cancer Research (AACR) Annual Meeting 2024
5/2/2024
07:00 am
nvcr
9.2%
BEAT
2/22/2024
07:00 am
nvcr
-3.2%
BEAT
10/26/2023
07:00 am
nvcr
-9.8%
BEAT
7/27/2023
07:00 am
nvcr
-15.7%
MISS
Earnings are essential to understanding the financial health of a company listed on any Stock Exchange. But what are Earnings, how are they calculated, when are they announced, and how are they used to make sound investment decisions? The answers are right here.
5/2
03:21 pm
Reiterates
Neutral
Wedbush
Low
1.3%
5/2
03:21 pm
Reiterates
Neutral
Wedbush
Low
1.3%
4/3
12:42 pm
Maintains
Overweight
Overweight
Wells Fargo
Low
1.1%
4/3
12:42 pm
Maintains
Overweight
Overweight
Wells Fargo
Low
1.1%
3/27
10:07 pm
Reiterates
Neutral
Wedbush
Medium
7.6%
3/27
10:07 pm
Reiterates
Neutral
Wedbush
Medium
7.6%
2/23
10:59 am
Maintains
In-Line
In-Line
Evercore ISI Group
Low
-0.4%
5/20
08:01 am
nvcr
Medium
Form 8-K NovoCure Ltd For: May 20
5/2
07:03 am
nvcr
Low
Form 10-Q NovoCure Ltd For: Mar 31
5/2
07:01 am
nvcr
Low
Form 8-K NovoCure Ltd For: May 02
4/22
04:03 pm
nvcr
Low
Form DEFA14A NovoCure Ltd
4/22
04:01 pm
nvcr
Low
Form DEF 14A NovoCure Ltd For: Jun 05
4/12
04:01 pm
nvcr
Medium
Form PRE 14A NovoCure Ltd For: Jun 05
3/27
07:00 am
nvcr
Medium
Form 8-K NovoCure Ltd For: Mar 27
3/5
04:10 pm
nvcr
Low
Form 4 NovoCure Ltd For: Mar 01 Filed by: GROENHUYSEN WILHELMUS CM
3/5
04:08 pm
nvcr
Low
Form 4 NovoCure Ltd For: Mar 01 Filed by: Leonard Frank X
Show more
Top News Gainers
1/16 Novocure Ltd (NASDAQ: NVCR) was downgraded by analysts at Zacks Investment Research from a "hold" rating to a "sell" rating. 11.0%
7/25 Q2/2019 6/30/2019 EPS -0.010 ZacksConsensus -0.070 ActVsEst 0.060 - Beat 8.6%
3/19 Novocure Announces Optune Lua™ as the Brand Name for the NovoTTF-100L™ System 8.2%
3/4 Novocure Ltd (NASDAQ: NVCR) was downgraded by analysts at BidaskClub from a "hold" rating to a "sell" rating. 7.8%
4/7 Novocure Ltd (NASDAQ: NVCR) is now covered by analysts at Piper Sandler. They set an "overweight" rating and a price target on the stock. 7.7%
5/23 FDA Approves the NovoTTF-100LTM System in Combination with Chemotherapy for the Treatment of Malignant Pleural Mesothelioma 7.3%
6/27 Novocure Ltd (NASDAQ: NVCR) was downgraded by analysts at BidaskClub from a "strong-buy" rating to a "buy" rating. 7.1%
8/14 Form 4 NovoCure Ltd For: Aug 12 Filed by: LEUNG GABRIEL 5.2%
10/31 NovoCure Limited (NVCR) CEO Asaf Danziger on Q3 2019 Results - Earnings Call Transcript [Seeking Alpha] 5.2%
1/7 Novocure Ltd (NASDAQ: NVCR) had its "buy" rating re-affirmed by analysts at Mizuho. They now have a $91.00 price target on the stock. 5.2%
Top News Decliners
4/30 Q1/2020 3/31/2020 EPS 0.040 ZacksConsensus 0.050 ActVsEst (0.010) - Miss -12.1%
3/20 German Federal Joint Committee Updates Medical Care Directive to include Tumor Treating Fields, establishing National Reimbursement for Optune in Germany -10.5%
4/7 Novocure Ltd (NASDAQ: NVCR) had its price target lowered by analysts at Wells Fargo & Co from $90.00 to $82.00. They now have an "overweight" rating on the stock. -9.6%
5/1 Novocure Ltd (NASDAQ: NVCR) had its "hold" rating re-affirmed by analysts at Oppenheimer Holdings Inc.. They now have a $78.00 price target on the stock. -8.4%
9/9 Novocure Announces 27 Presentations at the American Society for Radiation Oncology 2019 Annual Meeting -8.3%
3/10 Form 4 NovoCure Ltd For: Mar 06 Filed by: GROENHUYSEN WILHELMUS CM -8.1%
1/2 Novocure Ltd (NASDAQ: NVCR) was downgraded by analysts at Evercore ISI to an "outperform" rating. -7.9%
3/2 Form 4 NovoCure Ltd For: Feb 27 Filed by: Shah Pritesh -7.4%
10/25 Novocure Ltd (NASDAQ: NVCR) was upgraded by analysts at Zacks Investment Research from a "hold" rating to a "buy" rating. They now have a $79.00 price target on the stock. -6.6%
1/13 Form 8-K NovoCure Ltd For: Jan 10 -5.6%